Jazz Pharmaceuticals plc SEC filings JAZZ
Jazz Pharmaceuticals plc has 1,000 filings in SEC EDGAR's recent list, going back to Jun 20, 2017. Its latest annual report, Form ARS, was filed on Jun 8, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 2, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 9, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Aug 31, 2026 | Aug 26, 2026 |
| 8-K |
Current report
Other events
|
Aug 25, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 24, 2026 | Jul 23, 2026 |
| DEFA14A | Additional proxy material | Jul 14, 2026 | — |
| ARS | Annual report to shareholders | Jun 8, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Jun 8, 2026 | — |
| DEF 14A | Proxy statement | Jun 8, 2026 | Jul 23, 2026 |
| PRE 14A | Preliminary proxy statement | May 29, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Officer or director change
|
May 29, 2026 | May 25, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 5, 2026 | May 5, 2026 |
| 10-K/A | Amended annual report | Apr 24, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Feb 24, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 24, 2026 | Feb 24, 2026 |
| 8-K |
Current report
Results of operations
|
Jan 12, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Other events
|
Nov 17, 2025 | Nov 17, 2025 |
| 10-Q | Quarterly report | Nov 5, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2025 | Nov 5, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 28, 2025 | Oct 23, 2025 |
| 8-K |
Current report
Other events
|
Oct 22, 2025 | Oct 21, 2025 |
| UPLOAD | Letter from the SEC | Aug 8, 2025 | — |
| 10-Q | Quarterly report | Aug 6, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2025 | Aug 5, 2025 |
| CORRESP | Letter to the SEC | Jul 29, 2025 | — |
| 8-K |
Current report
Shareholder vote results
|
Jul 25, 2025 | Jul 24, 2025 |
| UPLOAD | Letter from the SEC | Jul 17, 2025 | — |
| DEFA14A | Additional proxy material | Jul 14, 2025 | — |
| DEFA14A | Additional proxy material | Jul 10, 2025 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 10, 2025 | Jul 8, 2025 |
| ARS | Annual report to shareholders | Jun 6, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Jun 6, 2025 | — |
| DEF 14A | Proxy statement | Jun 6, 2025 | Jul 24, 2025 |
| PRE 14A | Preliminary proxy statement | May 23, 2025 | Jul 24, 2025 |
| 10-Q | Quarterly report | May 7, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 6, 2025 | May 6, 2025 |
| 10-K/A | Amended annual report | Apr 25, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 21, 2025 | Apr 21, 2025 |
| SC TO-T/A | Filing | Apr 18, 2025 | — |
| SC TO-T/A | Filing | Apr 14, 2025 | — |
| SC TO-T/A | Filing | Apr 11, 2025 | — |
| SC TO-T/A | Filing | Apr 10, 2025 | — |
| SC TO-T/A | Filing | Apr 9, 2025 | — |
| 8-K |
Current report
Material agreement
|
Apr 8, 2025 | Apr 7, 2025 |
| SC TO-T/A | Filing | Apr 7, 2025 | — |
| CORRESP | Letter to the SEC | Apr 4, 2025 | — |
| SC TO-T/A | Filing | Apr 4, 2025 | — |
| SC TO-T/A | Filing | Apr 1, 2025 | — |
| SC TO-T/A | Filing | Mar 28, 2025 | — |
| SC TO-T | Filing | Mar 21, 2025 | — |
| SC TO-C | Filing | Mar 6, 2025 | — |
| SC TO-C | Filing | Mar 5, 2025 | — |
| SC TO-C | Filing | Mar 5, 2025 | — |
| 8-K/A |
Amended current report
Material agreement, Regulation FD disclosure
|
Mar 5, 2025 | Mar 4, 2025 |
| SC TO-C | Filing | Mar 5, 2025 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Mar 5, 2025 | Mar 4, 2025 |
| 10-K | Annual report | Feb 26, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 25, 2025 | Feb 25, 2025 |
| 8-K |
Current report
Results of operations
|
Jan 13, 2025 | Jan 13, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 16, 2024 | Dec 11, 2024 |
| 8-K |
Current report
Material agreement, New debt
|
Nov 26, 2024 | Nov 26, 2024 |
| 8-K |
Current report
Other events
|
Nov 21, 2024 | Nov 20, 2024 |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2024 | Nov 6, 2024 |
| 8-K |
Current report
Agreement ended
|
Oct 16, 2024 | Oct 10, 2024 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Sep 6, 2024 | Sep 3, 2024 |
| 8-K |
Current report
Other events
|
Aug 28, 2024 | Aug 27, 2024 |
| 10-Q | Quarterly report | Aug 1, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Jul 31, 2024 | Jul 31, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jul 26, 2024 | Jul 25, 2024 |
| DEFA14A | Additional proxy material | Jul 22, 2024 | — |
| 8-K |
Current report
Material agreement, New debt
|
Jul 22, 2024 | Jul 19, 2024 |
| ARS | Annual report to shareholders | Jun 14, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Jun 14, 2024 | — |
| DEF 14A | Proxy statement | Jun 14, 2024 | Jul 25, 2024 |
| PRE 14A | Preliminary proxy statement | Jun 3, 2024 | Jul 25, 2024 |
| 8-K |
Current report
Officer or director change
|
May 31, 2024 | May 31, 2024 |
| 10-Q | Quarterly report | May 2, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 1, 2024 | May 1, 2024 |
| 10-K/A | Amended annual report | Apr 26, 2024 | Dec 31, 2023 |
| 10-K | Annual report | Feb 28, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Feb 28, 2024 | Feb 28, 2024 |
| 8-K |
Current report
Officer or director change
|
Feb 27, 2024 | Feb 23, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Feb 21, 2024 | Feb 21, 2024 |
| 8-K |
Current report
Material agreement, New debt
|
Jan 25, 2024 | Jan 19, 2024 |
| 8-K |
Current report
Results of operations
|
Jan 8, 2024 | Jan 8, 2024 |
| 8-K |
Current report
Officer or director change
|
Dec 15, 2023 | Dec 11, 2023 |
| 10-Q | Quarterly report | Nov 8, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2023 | Nov 8, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 12, 2023 | Sep 6, 2023 |
| 10-Q | Quarterly report | Aug 9, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2023 | Aug 9, 2023 |
| DEFA14A | Additional proxy material | Jul 26, 2023 | — |
| CT ORDER | Filing | Jul 11, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 22, 2023 | Jun 22, 2023 |
| ARS | Annual report to shareholders | Jun 16, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Jun 16, 2023 | — |
| DEF 14A | Proxy statement | Jun 16, 2023 | — |
| PRE 14A | Preliminary proxy statement | Jun 6, 2023 | — |
| 10-Q | Quarterly report | May 10, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 10, 2023 | May 10, 2023 |
| 10-K/A | Amended annual report | May 1, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 1, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 1, 2023 | Mar 1, 2023 |
| 8-K |
Current report
Results of operations
|
Jan 9, 2023 | Jan 9, 2023 |
| 8-K |
Current report
Other events
|
Jan 4, 2023 | Jan 3, 2023 |
| 8-K |
Current report
Other events
|
Dec 21, 2022 | Dec 21, 2022 |
| 8-K |
Current report
Acquisition or sale of assets
|
Dec 5, 2022 | Nov 29, 2022 |
| 8-K |
Current report
Other events
|
Nov 14, 2022 | Nov 14, 2022 |
| 10-Q | Quarterly report | Nov 9, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2022 | Nov 9, 2022 |
| 8-K |
Current report
Other events
|
Oct 19, 2022 | Oct 19, 2022 |
| 10-Q | Quarterly report | Aug 3, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2022 | Aug 3, 2022 |
| DEFA14A | Additional proxy material | Jul 22, 2022 | — |
| DEFA14A | Additional proxy material | Jul 15, 2022 | — |
| DEFA14A | Additional proxy material | Jul 7, 2022 | — |
| DEFA14A | Additional proxy material | Jun 17, 2022 | — |
| DEFA14A | Additional proxy material | Jun 13, 2022 | — |
| DEF 14A | Proxy statement | Jun 13, 2022 | Jul 28, 2022 |
| PRE 14A | Preliminary proxy statement | May 31, 2022 | Jul 28, 2022 |
| 10-Q | Quarterly report | May 4, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Other events
|
May 4, 2022 | May 4, 2022 |
| 8-K |
Current report
Results of operations
|
May 4, 2022 | May 4, 2022 |
| 10-K/A | Amended annual report | May 2, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Other events
|
Apr 7, 2022 | Apr 7, 2022 |
| 8-K |
Current report
Other events
|
Mar 28, 2022 | Mar 28, 2022 |
| S-8 | Employee stock plan registration | Mar 2, 2022 | — |
| 10-K | Annual report | Mar 1, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 1, 2022 | Mar 1, 2022 |
| 8-K |
Current report
Results of operations
|
Jan 10, 2022 | Jan 10, 2022 |
| 10-Q | Quarterly report | Nov 9, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2021 | Nov 9, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Sep 24, 2021 | Sep 23, 2021 |
| DEF 14A | Proxy statement | Aug 30, 2021 | Sep 23, 2021 |
| PRE 14A | Preliminary proxy statement | Aug 19, 2021 | Sep 23, 2021 |
| 10-Q | Quarterly report | Aug 3, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2021 | Aug 3, 2021 |
| 8-K |
Current report
Other events
|
Jul 29, 2021 | Jul 28, 2021 |
| DEFA14A | Additional proxy material | Jul 26, 2021 | — |
| 8-K/A | Amended current report | Jul 19, 2021 | May 5, 2021 |
| DEFA14A | Additional proxy material | Jul 15, 2021 | — |
| DEFA14A | Additional proxy material | Jul 14, 2021 | — |
| DEFA14A | Additional proxy material | Jul 14, 2021 | — |
| 8-K |
Current report
Other events
|
Jul 1, 2021 | Jun 30, 2021 |
| DEFA14A | Additional proxy material | Jun 11, 2021 | — |
| DEF 14A | Proxy statement | Jun 11, 2021 | Jul 29, 2021 |
| PRE 14A | Preliminary proxy statement | Jun 1, 2021 | Jul 29, 2021 |
| S-8 | Employee stock plan registration | May 7, 2021 | — |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Unregistered share sale, Officer or director change, Other events
|
May 5, 2021 | May 5, 2021 |
| 10-Q | Quarterly report | May 4, 2021 | Mar 31, 2021 |
| 8-K |
Current report
Results of operations
|
May 4, 2021 | May 4, 2021 |
| 8-K |
Current report
Material agreement, New debt, Other events
|
Apr 29, 2021 | Apr 29, 2021 |
| 10-K/A | Amended annual report | Apr 23, 2021 | Dec 31, 2020 |
| 8-K |
Current report
Other events
|
Apr 23, 2021 | Apr 23, 2021 |
| 8-K |
Current report
Other events
|
Apr 22, 2021 | Apr 22, 2021 |
| DFAN14A | Filing | Apr 20, 2021 | — |
| 8-K |
Current report
Material agreement, Results of operations, Regulation FD disclosure, Other events
|
Apr 20, 2021 | Apr 20, 2021 |
| DFAN14A | Filing | Mar 23, 2021 | — |
| 8-K |
Current report
Other events
|
Mar 23, 2021 | Mar 22, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 22, 2021 | Mar 22, 2021 |
| DFAN14A | Filing | Feb 26, 2021 | — |
| DFAN14A | Filing | Feb 24, 2021 | — |
| DFAN14A | Filing | Feb 24, 2021 | — |
| DFAN14A | Filing | Feb 24, 2021 | — |
| S-8 | Employee stock plan registration | Feb 23, 2021 | — |
| 10-K | Annual report | Feb 23, 2021 | Dec 31, 2020 |
| DFAN14A | Filing | Feb 23, 2021 | — |
| 8-K |
Current report
Results of operations
|
Feb 23, 2021 | Feb 23, 2021 |
| DFAN14A | Filing | Feb 9, 2021 | — |
| DFAN14A | Filing | Feb 8, 2021 | — |
| DFAN14A | Filing | Feb 5, 2021 | — |
| DFAN14A | Filing | Feb 4, 2021 | — |
| DFAN14A | Filing | Feb 4, 2021 | — |
| DFAN14A | Filing | Feb 4, 2021 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Feb 4, 2021 | Feb 3, 2021 |
| DFAN14A | Filing | Feb 4, 2021 | — |
| DFAN14A | Filing | Feb 3, 2021 | — |
| 8-K |
Current report
Other events
|
Feb 3, 2021 | Feb 3, 2021 |
| 8-K |
Current report
Results of operations
|
Jan 12, 2021 | Jan 11, 2021 |
| 8-K |
Current report
Officer or director change
|
Nov 17, 2020 | Nov 13, 2020 |
| S-8 POS | Filing | Nov 3, 2020 | — |
| S-8 | Employee stock plan registration | Nov 2, 2020 | — |
| 10-Q | Quarterly report | Nov 2, 2020 | Sep 30, 2020 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2020 | Nov 2, 2020 |
| 10-Q | Quarterly report | Aug 4, 2020 | Jun 30, 2020 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2020 | Aug 4, 2020 |
| DEFA14A | Additional proxy material | Jul 22, 2020 | — |
| DEFA14A | Additional proxy material | Jul 21, 2020 | — |
| CT ORDER | Filing | Jun 30, 2020 | — |
| CT ORDER | Filing | Jun 30, 2020 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JAZZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ireland
- Headquarters
- Dublin
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1232524
- Former names
- JAZZ PHARMACEUTICALS INC (until Jan 18, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.